Antibody-Drug Conjugates Used in Breast Cancers | Zendy

Aram Abbas | Zendy; Marah F. Ibrahim | Zendy; Maher Saifo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antibody-Drug Conjugates Used in Breast Cancers

Author(s) -

Aram Abbas,

Marah F. Ibrahim,

Maher Saifo

Publication year - 2021

Publication title -

journal of oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.228

H-Index - 54

eISSN - 1687-8469

pISSN - 1687-8450

DOI - 10.1155/2021/9927433

Subject(s) - medicine , antibody drug conjugate , drug , breast cancer , antibody , drug delivery , cancer , oncology , targeted drug delivery , conjugate , cancer research , pharmacology , immunology , monoclonal antibody , mathematical analysis , chemistry , mathematics , organic chemistry

The prognosis of breast cancer has radically changed in recent years and continues to improve due to the broad application of effective therapies. New targeting strategies including targeted delivery of cytotoxic drugs via receptor-targeting agents have been developed. We summarize recent publications and developments of novel antibody-drug conjugates (ADCs) used to control breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research